For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| General and administrative | 12,876,175 | |||
| Research and development | 7,981,120 | |||
| Loss from operations | -20,857,295 | |||
| Change in fair value of warrant liabilities | -115,301 | |||
| Realized foreign currency translation loss from dissolution of subsidiaries | -7,171 | |||
| Foreign currency gain | 30,376 | |||
| Other income | 380,532 | |||
| Change in fair value of derivative warrant liability | 416,619 | |||
| Interest and dividends, net | 327,193 | |||
| Other income, net | 429,612 | |||
| Loss before income taxes | -20,427,683 | |||
| Net loss | -20,427,683 | |||
| Foreign currency translation | 18,766 | |||
| Comprehensive loss | -20,408,917 | |||
| Basic EPS | -2.91 | |||
| Diluted EPS | -2.91 | |||
| Basic Average Shares | 7,031,050 | |||
| Diluted Average Shares | 7,031,050 | |||
Pasithea Therapeutics Corp. (KTTAW)
Pasithea Therapeutics Corp. (KTTAW)